Stock Scorecard
Stock Summary for Zura Bio Ltd - Class A (ZURA) - $6.62 as of 3/2/2026 12:44:54 PM EST
Total Score
12 out of 30
Safety Score
16 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for ZURA
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for ZURA
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for ZURA
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for ZURA
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for ZURA (16 out of 100)
| Stock Price Rating (Max of 10) | 4 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 2 |
| Book Value (Max of 10) | 2 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 5 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | -10 |
Latest News for for ZURA
Financial Details for ZURA
Company Overview |
|
|---|---|
| Ticker | ZURA |
| Company Name | Zura Bio Ltd - Class A |
| Country | N/A |
| Description | Zura Bio Limited (Ticker: ZURA) is a biotechnology firm dedicated to developing transformative therapies for autoimmune disorders and rare diseases. The company boasts a robust pipeline, focusing on advancing its lead drug candidates through rigorous clinical trials leveraging state-of-the-art research methodologies. With a seasoned management team and strategic partnerships, Zura Bio is well-positioned to meet significant unmet medical needs, contributing meaningfully to the biopharmaceutical landscape while driving value for its investors amidst a dynamic market environment. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | 3/24/2026 |
Stock Price History |
|
| Last Day Price | 6.62 |
| Price 4 Years Ago | 10.21 |
| Last Day Price Updated | 3/2/2026 12:44:54 PM EST |
| Last Day Volume | 406,180 |
| Average Daily Volume | 754,808 |
| 52-Week High | 6.88 |
| 52-Week Low | 0.97 |
| Last Price to 52 Week Low | 582.47% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 26.08 |
| Sector PE | 46.86 |
| 5-Year Average PE | 10.38 |
| Free Cash Flow Ratio | 3.09 |
| Industry Free Cash Flow Ratio | 12.68 |
| Sector Free Cash Flow Ratio | 25.71 |
| Current Ratio Most Recent Quarter | 5.58 |
| Total Cash Per Share | 2.14 |
| Book Value Per Share Most Recent Quarter | 1.66 |
| Price to Book Ratio | 3.65 |
| Industry Price to Book Ratio | 50.08 |
| Sector Price to Book Ratio | 52.77 |
| Price to Sales Ratio Twelve Trailing Months | 0.00 |
| Industry Price to Sales Ratio Twelve Trailing Months | 38.92 |
| Sector Price to Sales Ratio Twelve Trailing Months | 22.39 |
| Analyst Buy Ratings | 5 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 65,023,000 |
| Market Capitalization | 430,452,260 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 13.18% |
| Reported EPS 12 Trailing Months | -0.65 |
| Reported EPS Past Year | -0.53 |
| Reported EPS Prior Year | -0.55 |
| Net Income Twelve Trailing Months | -62,520,000 |
| Net Income Past Year | -52,403,000 |
| Net Income Prior Year | -60,360,000 |
| Quarterly Revenue Growth YOY | 0.00% |
| 5-Year Revenue Growth | 0.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 139,017,000 |
| Total Cash Past Year | 176,498,000 |
| Total Cash Prior Year | 99,806,000 |
| Net Cash Position Most Recent Quarter | 139,017,000 |
| Net Cash Position Past Year | 168,742,000 |
| Long Term Debt Past Year | 7,756,000 |
| Long Term Debt Prior Year | 7,756,000 |
| Total Debt Most Recent Quarter | 0 |
| Equity to Debt Ratio Past Year | 0.95 |
| Equity to Debt Ratio Most Recent Quarter | 1.00 |
| Total Stockholder Equity Past Year | 146,815,000 |
| Total Stockholder Equity Prior Year | 59,330,000 |
| Total Stockholder Equity Most Recent Quarter | 108,243,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -53,501,999 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.82 |
| Free Cash Flow Past Year | -28,151,000 |
| Free Cash Flow Prior Year | -23,054,000 |
Options |
|
| Put/Call Ratio | 1.71 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.31 |
| MACD Signal | 0.29 |
| 20-Day Bollinger Lower Band | 2.59 |
| 20-Day Bollinger Middle Band | 4.76 |
| 20-Day Bollinger Upper Band | 6.93 |
| Beta | 0.20 |
| RSI | 0.00 |
| 50-Day SMA | 2.82 |
| 150-Day SMA | 3.96 |
| 200-Day SMA | 5.63 |
System |
|
| Modified | 2/26/2026 12:02:05 PM EST |